QDEL - Quidel Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
54.38
+2.14 (+4.10%)
As of 11:12AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close52.24
Open52.62
Bid54.05 x 1200
Ask54.16 x 1100
Day's Range52.62 - 54.49
52 Week Range41.50 - 77.63
Volume65,233
Avg. Volume301,319
Market Cap2.139B
Beta (3Y Monthly)1.78
PE Ratio (TTM)54.49
EPS (TTM)1.00
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.20
Trade prices are not sourced from all markets
  • 7 Cheap Stocks to Buy on the Dip
    Kiplinger7 days ago

    7 Cheap Stocks to Buy on the Dip

    Despite a rocky 2018, many analysts still are bullish on the investing outlook for 2019. Yes, the final quarter of last year was miserable - but the upshot is that it left investors with numerous higher-quality cheap stocks to buy. Blackstone's Joseph Zidle, Managing Director and Investment Strategist in the Private Wealth Solutions group, told CNBC, "This is a buying opportunity. We see the market (the Standard & Poor's 500-stock index) up 15 percent in 2019. This is just not a recessionary environment." Similarly, Goldman Sachs Chief U.S. Equity Strategist David Kostin writes, "The low starting level and valuation of the market suggest positive returns to US equities in the coming year." He believes that ongoing U.S. economic expansion will lift the S&P; 500 to 3,000 by the end of 2019. Several other market analysts see the market heading higher in the year to come. However, investors still need to be savvy about which stocks to buy and which to avoid. That's why we turned to TipRanks to pinpoint buy-rated stocks with significant support from the analyst community. Here are seven cheap stocks to buy, according to top-rated Wall Street analysts. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • How Much Did Quidel Corporation’s (NASDAQ:QDEL) CEO Pocket Last Year?
    Simply Wall St.9 days ago

    How Much Did Quidel Corporation’s (NASDAQ:QDEL) CEO Pocket Last Year?

    Doug Bryant has been the CEO of Quidel Corporation (NASDAQ:QDEL) since 2009. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • Business Wire11 days ago

    Quidel Announces Preliminary Revenue for Fourth Quarter 2018

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2018 to be in the range of $132 million to $133 million. “We had another great quarter, and a remarkable year, a year in which our efforts and excellent performance were driven significantly by the integration of the acquired Triage assets.

  • Business Wire16 days ago

    Quidel to Present at 37th Annual J.P. Morgan Healthcare Conference

    Quidel Corporation , a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 37th Annual J.P.

  • Hedge Funds Aren’t Crazy About Quidel Corporation (QDEL) Anymore
    Insider Monkey29 days ago

    Hedge Funds Aren’t Crazy About Quidel Corporation (QDEL) Anymore

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]

  • Business Wirelast month

    Quidel Receives CE Mark for Its Point-of-Care Sofia® Quantitative Vitamin D Assay for Use With Sofia Instrument

    SAN DIEGO-- -- Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has received CE Mark for its Sofia Quantitative Vitamin D FIA for use with the Sofia fluorescent immunoassay analyzer for the quantitative determination of total 25-OH vitamin D from serum samples. The test is intended for use with ...

  • Business Wirelast month

    Quidel Receives CE Mark for Point-of-Care Sofia® 2 Lyme+ Fluorescent Immunoassay for Use with Sofia 2 Instrument

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel’s Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii from serum and plasma specimens. The test is specifically developed for the European market and intended for use with the Sofia 2 analyzer to aid in the diagnosis of Lyme disease.

  • Zackslast month

    Here's Why You Should Buy Express Scripts (ESRX) Stock Now

    Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zackslast month

    Here's Why You Should Hold Allscripts Stock in Your Portfolio

    Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.

  • Business Wirelast month

    Quidel Announces the Availability of Triage® PLGF Assay for Use with Quidel’s Triage® MeterPro Instrumented System

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the manufacturing of Quidel Triage® PLGF Test is set to resume in 2019 and be commercially available outside the US for clinical use in Q1 2019. Knowledge of maternal circulating concentration of Placental Growth Factor (PLGF), a biomarker for placental dysfunction, aids in the early and accurate diagnosis of preterm pre-eclampsia and helps clinicians to accurately risk-stratify pregnant women resulting in more efficient use of healthcare resources and the potential for cost-saving to the healthcare system.

  • Zackslast month

    Express Scripts Announces 3-Year Agreement With Walmart

    Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.

  • Zackslast month

    Quidel (QDEL) Catches Eye: Stock Jumps 6.7%

    Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.

  • Zackslast month

    BD Gets Enterprise Level Cybersecurity Assessment From UL

    BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.

  • Simply Wall St.last month

    A Look At The Intrinsic Value Of Quidel Corporation (NASDAQ:QDEL)

    In this article I am going to calculate the intrinsic value of Quidel Corporation (NASDAQ:QDEL) by taking the expected future cash flows and discounting them to their present value. I Read More...

  • Zackslast month

    Here's Why Investors Should Hold Masimo (MASI) Stock Now

    Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

  • Business Wirelast month

    Quidel to Hold BNP Supply Agreement Update Conference Call on December 10, 2018

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will hold a conference call on December 10, 2018 to discuss the San Diego Superior Court’s ruling related to Quidel’s BNP Supply Agreement with Beckman. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, December 10th to discuss the outcome. Quidel’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.

  • Business Wirelast month

    Quidel Comments on California Court Ruling

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the San Diego Superior Court (the “Court”) stated that it intends to enter an order granting Beckman’s motion for summary adjudication relating to the agreement for the supply of antibodies and other inputs related to, and distribution of, the Triage® BNP Test for the Beckman Coulter Access Family of Immunoassay Systems, between Quidel and Beckman (the “Beckman Agreement”). Specifically, the Court stated that it intends to rule that a provision of the Beckman Agreement restricting Beckman from manufacturing or selling another BNP or NT-proBNP assay is void as a matter of law.

  • Here's Why You Should Hold Pacific Biosciences (PACB) Now
    Zackslast month

    Here's Why You Should Hold Pacific Biosciences (PACB) Now

    Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.

  • Here's Why You Should Invest in Accuray (ARAY) Stock Now
    Zackslast month

    Here's Why You Should Invest in Accuray (ARAY) Stock Now

    Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.

  • Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
    Zacks2 months ago

    Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth

    Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.

  • Business Wire2 months ago

    Quidel Receives CE Mark for TriageTrueTM High Sensitivity Troponin I Test, Its Next-Generation Diagnostic Assay for Aid in Diagnosis of Myocardial Infarction for Use with Quidel’s Triage® MeterPro Instrumented System

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received CE Mark for its TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be used as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel’s Triage® MeterPro instrumented system. MI, or heart attack, occurs when a part of the heart muscle doesn’t receive enough blood flow.

  • Cardinal Health to Highlight Cost-Control Approach in ASHP
    Zacks2 months ago

    Cardinal Health to Highlight Cost-Control Approach in ASHP

    Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.